Featured News & Highlights

Experienced oncology teams know that successful country selection depends on much more than identifying where a study can start quickly. Here are four factors that can be under-considered when developing a country strategy for an oncology study in Europe.

FDA’s February 2026 New England Journal of Medicine article, “One Pivotal Trial, the New Default Option for…

One of the more interesting themes emerging from ASCO 2026 was that some of the most important progress in precision oncology care is not about adding more/new treatment—it is about determining when less treatment is enough.

Over the last 10-15 years, the amount of time spent between clinical trials, including administrative closeout and key decision points, has significantly increased. A new initiative by FDA aims to reduce “dead time” between clinical trial phases.

Many sponsors encounter a consistent challenge: ADC clinical trials introduce a level of operational complexity that goes well beyond traditional oncology trials.

Historically used more frequently in exploratory analyses, Bayesian approaches are now increasingly recognized as viable frameworks for primary analysis in drug and biologic development—when appropriately designed and justified.

It sounds like a small administrative detail—but in practice, URL ownership shapes how your trial operates from day one through closeout. It can influence everything from study startup timelines to change control processes, migration costs, and long-term data governance.